Lembcke B, Lamberts R, Wöhler J, Creutzfeldt W
Division of Gastroenterology and Endocrinology, Georg-August-University, Göttingen, Federal Republic of Germany.
Res Exp Med (Berl). 1991;191(6):389-404. doi: 10.1007/BF02576694.
Effects of the two absorbable alpha-glucosidase inhibitors miglitol (BAYm1099) and emiglitate (BAYo1248) on hepatic and muscular glycogen concentrations were investigated in the rat after 3, 7, and 28 days. Both compounds were (orally) administered at very high doses (5-50-500 mg/kg b.wt.). In a second experiment, glycogen storage after oral administration of acarbose (1000 mg/kg b.wt.) was studied after 7 days. In a third protocol, hepatic glycogen concentrations were investigated in the fed rat after 7 days of either inhibitor at the respective highest dosage. In fasted rats, emiglitate induced a significant, dose-dependent increase of hepatic glycogen concentrations, which--at the dose of 500 mg/kg b.wt.--were present after 3, 7, and 28 days, but resulted in a significant increase of the liver weight after 28 days only. Light and electron microscopy proved that the increase in hepatic glycogen was due to lysosomal storage of glycogen only. Emiglitate in the amount of 5 mg/kg b.wt. did not induce significant changes either of glycogen concentrations or at the EM-level. While emiglitate also increased hepatic glycogen at a dosage of 50 mg/kg b.wt., miglitol led to significant storage of hepatic glycogen after 3, 7, or 28 days at the highest dose only. With miglitol (500 mg/kg b.wt.), only insignificant lysosomal storage of glycogen could be detected by electron and light microscopy, and liver weight was essentially unaffected. Both compounds displayed a dose-dependent tendency towards higher glycogen concentrations in the soleus muscle, which was significant with the highest dosage of either inhibitor. At an oral dose of o.i.d. 1000 mg/kg b.wt., the almost unabsorbable alpha-glucosidase inhibitor acarbose induced significantly increased glycogen concentrations both in the liver and in the soleus muscle after 7 days. With respect to an enormous enlargement of the lysosomes (EM) and in the absence of cytoplasmatic alpha-glycogen, this accumulation of glycogen must be attributed to lysosomal storage. In fed rats, all alpha-glucosidase inhibitors investigated significantly decreased postprandial hepatic glycogen concentrations (emiglitate greater than miglitol greater than acarbose), thereby reflecting the modulation of absorption. It is concluded that in the rat acarbose at approximately 1000 x ED50 may penetrate the intestinal mucosa at amounts significant enough to induce lysosomal storage of glycogen. Miglitol may cause some hepatocellular, lysosomal glycogen storage at a dose of 500 mg/kg b.wt., but no glycogen storage could be proven up to 100 x ED50 over 28 days.(ABSTRACT TRUNCATED AT 400 WORDS)
研究了两种可吸收的α-葡萄糖苷酶抑制剂米格列醇(BAYm1099)和依米格列他(BAYo1248)在大鼠体内作用3、7和28天后对肝脏和肌肉糖原浓度的影响。两种化合物均以非常高的剂量(5 - 50 - 500 mg/kg体重)口服给药。在第二个实验中,研究了口服阿卡波糖(1000 mg/kg体重)7天后的糖原储存情况。在第三个实验方案中,在分别给予两种抑制剂各自最高剂量7天后,研究了喂食大鼠的肝脏糖原浓度。在禁食大鼠中,依米格列他可引起肝脏糖原浓度显著的剂量依赖性增加,在500 mg/kg体重剂量下,3天、7天和28天后均出现此现象,但仅在28天后导致肝脏重量显著增加。光镜和电镜检查证明肝脏糖原增加仅是由于糖原的溶酶体储存。5 mg/kg体重剂量的依米格列他对糖原浓度或电镜水平均未引起显著变化。虽然50 mg/kg体重剂量的依米格列他也增加了肝脏糖原,但米格列醇仅在最高剂量下3天、7天或28天后导致肝脏糖原显著储存。对于米格列醇(500 mg/kg体重),通过电子显微镜和光镜仅检测到极少量的糖原溶酶体储存,肝脏重量基本未受影响。两种化合物均呈现出在比目鱼肌中糖原浓度随剂量增加的趋势,两种抑制剂的最高剂量时此趋势显著。口服剂量为1000 mg/kg体重时,几乎不吸收的α-葡萄糖苷酶抑制剂阿卡波糖在7天后可显著增加肝脏和比目鱼肌中的糖原浓度。鉴于溶酶体极大增大(电镜检查)且缺乏细胞质α-糖原,这种糖原积累必定归因于溶酶体储存。在喂食大鼠中,所有研究的α-葡萄糖苷酶抑制剂均显著降低餐后肝脏糖原浓度(依米格列他>米格列醇>阿卡波糖),从而反映了对吸收的调节作用。结论是,在大鼠中,约1000倍ED50剂量的阿卡波糖可能以足以诱导糖原溶酶体储存的量穿透肠黏膜。米格列醇在500 mg/kg体重剂量时可能导致一些肝细胞溶酶体糖原储存,但在28天内高达100倍ED50剂量时未证实有糖原储存。(摘要截断于400字)